Christopher T. Turner

Christopher T. Turner

Auto-generated profile, based on publicly available information

Christopher T. Turner

Centre for Heart Lung Innovation, St. Paul’s Hospital, University of British Columbia, Vancouver, BC, Canada

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2019 in JACC: Cardiovascular Imaging
Verified
Journal Article
Closed access
SSStephanie L. Sellers
Stephanie L. Sellers
CTChristopher T. Turner
Christopher T. Turner
JSJanarthanan Sathananthan
Janarthanan Sathananthan
TCTimothy R.G. Cartlidge
Timothy R.G. Cartlidge
FSFrances Sin
Frances Sin
JLJonathon A. Leipsic
Jonathon A. Leipsic

1 January 2019 in Matrix Biology
Verified
Journal Article
Closed access
CTChristopher T. Turner
Christopher T. Turner
DLDarielle Lim
Darielle Lim
DGDavid James Granville
David James Granville

12 January 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
SHSho Hiroyasu
Sho Hiroyasu
MZMatthew R. Zeglinski
Matthew R. Zeglinski
HZHongyan Zhao
Hongyan Zhao
MPMegan A. Pawluk
Megan A. Pawluk
CTChristopher T. Turner
Christopher T. Turner
DGDavid James Granville
David James Granville
Pemphigoid diseases refer to a group of severe autoimmune skin blistering diseases characterized by subepidermal blistering and loss of dermal-epidermal adhesion induced by autoantibody and immune cell infiltrate at the dermal-epidermal junction and upper dermis. Here, we explore the role of the immune cell-secreted serine protease, granzyme B, in pemphigoid disease pathogenesis using three independent murine models. In all models, granzyme B knockout or topical pharmacological inhibition significantly reduces total blistering area compared to controls. In vivo and in vitro studies show that granzyme B contributes to blistering by degrading key anchoring proteins in the dermal-epidermal junction that are necessary for dermal-epidermal adhesion. Further, granzyme B mediates IL-8/macrophage inflammatory protein-2 secretion, lesional neutrophil infiltration, and lesional neutrophil elastase activity. Clinically, granzyme B is elevated and abundant in human pemphigoid disease blister fluids and lesional skin. Collectively, granzyme B is a potential therapeutic target in pemphigoid diseases.

30 May 2018 in Experimental & Molecular Medicine
Verified
Journal Article
Open access
PDF file
YSYue Shen
Yue Shen
MZMatthew R. Zeglinski
Matthew R. Zeglinski
CTChristopher T. Turner
Christopher T. Turner
SRSheetal A. Raithatha
Sheetal A. Raithatha
ZWZhenguo Wu
Zhenguo Wu
DGDavid James Granville
David James Granville
Granzyme B (GzmB) is a serine protease that has long been thought to function exclusively in lymphocyte-mediated apoptosis. In recent years, this paradigm has been revisited due to the recognition that GzmB accumulates in the extracellular milieu in many autoimmune and chronic inflammatory disorders, and contributes to impaired tissue remodeling due to the cleavage of extracellular matrix proteins. Knockout studies suggest that GzmB-mediated cleavage of decorin (DCN) contributes to impaired collagen fibrillogenesis and remodeling. As DCN is anti-fibrotic and contributes to reduced hypertrophic scarring, GzmB-induced DCN cleavage could play a role in wound healing following burn injury. In the present study, a novel, gel-formulated, first-in-class small-molecule inhibitor of GzmB, VTI-1002, was assessed in a murine model of impaired, diabetic burn wound healing. VTI-1002 exhibited high specificity, potency, and target selectivity. Gel-formulated VTI-1002 was able to penetrate the stratum corneum and was retained in the skin with minimal systemic absorption. Daily topical administration of VTI-1002 gel for 30 days following thermal injury showed significantly accelerated wound closure, increased DCN protein levels, and collagen organization that was translated into significantly increased wound tensile strength compared to controls. Overall, VTI-1002 gel was well-tolerated in vivo and no adverse events were observed. Topical application of VTI-1002 represents a novel therapeutic approach for the treatment of cutaneous burn wounds.

1 January 2021 in Journal of Investigative Dermatology
Verified
Journal Article
Closed access
CTChristopher T. Turner
Christopher T. Turner
MZMatthew R. Zeglinski
Matthew R. Zeglinski
KRKatlyn C. Richardson
Katlyn C. Richardson
SSStephanie Santacruz
Stephanie Santacruz
SHSho Hiroyasu
Sho Hiroyasu
DGDavid James Granville
David James Granville

1 April 2013 in Journal of Investigative Dermatology
Verified
Journal Article
Closed access
Zlatko KopeckiZlatko Kopecki
Zlatko Kopecki
NRNadira Ruzehaji
Nadira Ruzehaji
CTChristopher Turner
Christopher Turner
HIHioraki Iwata
Hioraki Iwata
Ralf J. LudwigRalf J. Ludwig
Ralf J. Ludwig
ACAllison Cowin
Allison Cowin